Nucleic acid molecules encoding a humanized antibody
AssigneesAC Immune SA, Genetech, Inc.
InventorsAndrea Pfeifer, Maria Pihlgren, Andreas Muhs, Ryan Watts
Life of this patent
Estimating the term…
Abstract
The present invention is related to chimeric and humanized antibody and to methods and compositions for the therapeutic and diagnostic use in the treatment of amyloidosis, a group of disorders and abnormalities associated with amyloid protein such as Alzheimer's disease.
Claims47
A nucleic acid molecule comprising a nucleotide sequence encoding a Light Chain Variable Region (LCVR) or a fragment thereof of an antibody which is capable of specifically binding to beta-amyloid 1-40 and to monomeric, oligomeric or polymeric forms of beta-amyloid 1-42, wherein said LCVR or fragment thereof comprises:
- (i) human- or primate-derived framework regions,
- (ii) an LCVR CDR1 comprising the amino acid sequence of SEQ ID NO:
- 4,
- (iii) an LCVR CDR2 comprising the amino acid sequence of SEQ ID NO:
- 5 or the amino acid sequence of SEQ ID NO:
- 5 with one amino acid substitution, and
- (iv) an LCVR CDR3 comprising the amino acid sequence of SEQ ID NO:
- 6,
- and wherein said LCVR or fragment thereof comprises an amino acid sequence that is at least 98% identical to the amino acid sequence of SEQ ID NO:
- 12.
A nucleic acid molecule comprising a nucleotide sequence encoding a Heavy Chain Variable Region (HCVR) or a fragment thereof of an antibody which is capable of specifically binding to beta-amyloid 1-40 and to monomeric, oligomeric or polymeric forms of beta-amyloid 1-42, wherein said HCVR or fragment thereof comprises:
- (i) human- or primate-derived framework regions,
- (ii) an HCVR CDR1 comprising the amino acid sequence of SEQ ID NO:
- 1,
- (iii) an HCVR CDR2 comprising the amino acid sequence of SEQ ID NO:
- 2, and
- (iv) an HCVR CDR3 comprising the amino acid sequence of SEQ ID NO:
- 3,
- and wherein said HCVR or fragment thereof comprises an amino acid sequence that is at least 98% identical to the amino acid sequence of SEQ ID NO:
- 15.
A nucleic acid molecule comprising a nucleotide sequence encoding an antibody or a fragment thereof which antibody or fragment thereof is capable of specifically binding to beta-amyloid peptide 1-40 and to monomeric, oligomeric or polymeric forms of beta-amyloid 1-42, wherein said antibody or fragment thereof comprises:
- (i) a Light Chain Variable Region (LCVR) comprising an amino acid sequence that is at least 98% identical to the amino acid sequence of SEQ ID NO:
- 12 and an Heavy Chain Variable Region (HCVR) comprising an amino acid sequence that is at least 98% identical to the amino acid sequence of SEQ ID NO:
- 15,
- (ii) an HCVR CDR1 comprising the amino acid sequence of SEQ ID NO:
- 1,
- (iii) an HCVR CDR2 comprising the amino acid sequence of SEQ ID NO:
- 2,
- (iv) an HCVR CDR3 comprising the amino acid sequence of SEQ ID NO:
- 3,
- (v) an LCVR CDR1 comprising the amino acid sequence of SEQ ID NO:
- 4,
- (vi) an LCVR CDR2 comprising the amino acid sequence of SEQ ID NO:
- 5 or the amino acid sequence of SEQ ID NO:
- 5 with one amino acid substitution, and
- (vii) an LCVR CDR3 comprising the amino acid sequence of SEQ ID NO:
- 6.
A nucleic acid molecule comprising a nucleotide sequence encoding a Light Chain Variable Region (LCVR) or a fragment thereof of an antibody which is capable of specifically binding to beta-amyloid 1-40 and to monomeric, oligomeric or polymeric forms of beta-amyloid 1-42, wherein said LCVR comprises the amino acid sequence of SEQ ID NO:
- 12.
A nucleic acid molecule comprising a nucleotide sequence encoding a Heavy Chain Variable Region (HCVR) or a fragment thereof of an antibody which is capable of specifically binding to beta-amyloid 1-40 and to monomeric, oligomeric or polymeric forms of beta-amyloid 1-42, wherein said HCVR comprises the amino acid sequence of SEQ ID NO:
- 15.
A nucleic acid molecule comprising a nucleotide sequence encoding an antibody or a fragment thereof which antibody or fragment thereof is capable of specifically binding to beta-amyloid peptide 1-40 and to monomeric, oligomeric or polymeric forms of beta-amyloid 1-42, wherein said antibody comprises a Light Chain Variable Region (LCVR) comprising the amino acid of SEQ ID NO:
- 12 and a Heavy Chain Variable Region (HCVR) comprising the amino acid sequence of SEQ ID NO:
- 15.
A nucleic acid molecule comprising a nucleotide sequence encoding an antibody or a fragment thereof which antibody or fragment thereof is capable of specifically binding to beta-amyloid 1-40 and to monomeric, oligomeric or polymeric forms of beta-amyloid 1-42, wherein said antibody or fragment thereof comprises:
- (i) human- or primate-derived framework regions,
- (ii) an LCVR CDR1 comprising the amino acid sequence of SEQ ID NO:
- 4,
- (iii) an LCVR CDR2 comprising the amino acid sequence of SEQ ID NO:
- 5 or the amino acid sequence of SEQ ID NO:
- 5 with one amino acid substitution,
- (iv) an LCVR CDR3 comprising the amino acid sequence of SEQ ID NO:
- 6, and
- (v) an HCVR comprising the amino acid sequence of SEQ ID NO:
- 15.
A nucleic acid molecule comprising a nucleotide sequence encoding an antibody or a fragment thereof which antibody or fragment thereof is capable of specifically binding to beta-amyloid 1-40 and to monomeric, oligomeric or polymeric forms of beta-amyloid 1-42, wherein said antibody or fragment thereof comprises:
- (i) human- or primate-derived framework regions,
- (ii) an HCVR CDR1 comprising the amino acid sequence of SEQ ID NO:
- 1,
- (iii) an HCVR CDR2 comprising the amino acid sequence of SEQ ID NO:
- 2,
- (iv) an HCVR CDR3 comprising the amino acid sequence of SEQ ID NO:
- 3, and
- (v) a LCVR comprising the amino acid sequence of SEQ ID NO:
- 12.
Dependencies are inferred from the claim text.